Fate Therapeutics, Inc. (Nasdaq:FATE), a biopharmaceutical company engaged in the discovery and development of adult stem cell modulators to treat orphan diseases, reported therapeutic program updates and announced financial results for the fourth quarter and year ended December 31, 2013. Fate Therapeutics Inc (NASDAQ:FATE) shares after opening at $10.75 moved to $11.02 on last trade day and at the end of the day closed at $10.43. Company price to sales ratio in past twelve months was calculated as 8.23 and price to cash ratio as 0.69. Fate Therapeutics Inc (NASDAQ:FATE) showed a positive weekly performance of 15.38%.
Trevena, Inc. (NASDAQ: TRVN), a clinical stage pharmaceutical company focused on the discovery and development of G-protein coupled receptor (GPCR) biased ligands, announced that it will host a conference call on Thursday, March 20, 2014 at 11:00 a.m. Eastern Time to discuss corporate updates and financial results for the year ended December 31, 2013. Trevena Inc (NASDAQ:TRVN) shares fell -6.84% in last trading session and ended the day on $8.45. TRVN return on equity ratio is recorded as 68.10% and its return on assets is -90.30%.
On March 3, 2014, OHR Pharmaceutical Inc (NASDAQ:OHRP) teamed up with Cold Spring Harbor Laboratory (CSHL) to announce the establishment of DepYmed Inc., a new joint venture to develop trodusquemine and related analogs. The Company informed that the new joint venture will be a private entity, initially with equal ownership by Ohr and CSHL. “Cold Spring Harbor Laboratory is a world class research center that has a track record of establishing successful commercial ventures in the biopharma space,” said Irach Taraporewala, President and CEO of Ohr. “We are very pleased to be working with Dr. Nicholas Tonks who is one of the leading authorities on the protein tyrosine phosphatase (PTP) family of enzymes. Dr. Tonks discovered PTP1B, the primary target for trodusquemine. Setting up this joint venture is the optimal way to create shareholder value from this exciting asset and enable it to obtain the appropriate resources. At the same time, Ohr remains focused on the execution of our core strategy to develop novel ophthalmology products. OHR Pharmaceutical Inc (NASDAQ:OHRP) shares moved down -5.65% in last trading session and was closed at $18.54, while trading in range of $18.41-$20.00. OHR Pharmaceutical Inc (NASDAQ:OHRP) year to date performance is 135.28%.
Investment analysts at Oppenheimer increased their target price on shares of Insys Therapeutics (NASDAQ:INSY) from $46.00 to $88.00 in a note issued to investors on Wednesday, ARN reports. Oppenheimer’s target price suggests a potential upside of 5.43% from the company’s current price. Insys Therapeutics Inc (NASDAQ:INSY) weekly performance is -11.29%. On last trading day company shares ended up $67.23. Insys Therapeutics Inc (NASDAQ:INSY) distance from 50-day simple moving average is 16.43%. Analysts mean target price for the company is $93.50.
Leave a Reply